Amlitelimab (FUT8-KO)
Amlitelimab (FUT8-KO) is Amlitelimab (HY-P99434) expressed in cells with the fucosyltransferase 8 gene (FUT8) knocked out. Amlitelimab (KY1005) is a monoclonal antibody (mAb) against OX40 ligand (OX40L). Amlitelimab inhibits the OX40-OX40L interaction and can be used for research on atopic dermatitis.
For research use only. We do not sell to patients.
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All Orexin Receptor (OX Receptor) Isoforms
More
Biological Activity
-
IgG4-kappa
Chemical Information
-
SMILES
[Amlitelimab (FUT8-KO)]
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
[2]. Saghari M, et al. OX40L Inhibition Suppresses KLH-driven Immune Responses in Healthy Volunteers: A Randomized Controlled Trial Demonstrating Proof-of-Pharmacology for KY1005. Clin Pharmacol Ther. 2022 May;111(5):1121-1132. [Content Brief]
[3]. Tkachev V, et al. Combined OX40L and mTOR blockade controls effector T cell activation while preserving Treg reconstitution after transplant. Sci Transl Med. 2017 Sep 20;9(408):eaan3085. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)